Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25:1650–1656.
   PubMed Web of Science ®Google Scholar
• Carpelan-Holmstrom M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005;54:385–387.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921.
   PubMed Web of Science ®Google Scholar
• Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266–4276.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Von Hoff DD. Tumor stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007;6:1186–1197.
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–1806.
   PubMed Web of Science ®Google Scholar
• Yeo CJ, Cameron JL, Lillemore KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg. 1995;221:721–731.
   PubMed Web of Science ®Google Scholar
• Shaib Y, Davilla J, Naumann C, El-Serag H. The impact of curative intent surgery on the survival of pancreatic cancer patients: a US population-based study. Am J Gasteroenterol. 2007;102:1377–1382.
   PubMed Web of Science ®Google Scholar
• Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gasteroenterol Hepatol. 2009;6:699–708.
   PubMed Web of Science ®Google Scholar
• Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–1617.
   PubMed Web of Science ®Google Scholar
• Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–1057.
   PubMed Web of Science ®Google Scholar
• Burris HA III, Moore MJ, Andresen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer. 2002;94:902–910.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–5518.
   PubMed Web of Science ®Google Scholar
• Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–3516.
   PubMed Web of Science ®Google Scholar
• Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639–1645.
   PubMed Web of Science ®Google Scholar
• Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776–3783.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418–429.
   PubMed Web of Science ®Google Scholar
• Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457–1461.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer. N Engl J Med. 2009;361:2094–2096.
   PubMed Web of Science ®Google Scholar
• Wani MC, Horwitz SB. Nature as a remarkable chemist: a personal story of the discovery and development of Taxol. Anticancer Drugs. 2014;25:482–487.
   PubMed Web of Science ®Google Scholar
• Horwitz B. Mechanism of action of Taxol. Trends Pharmacol Sci. 1992;13:134–136.
   PubMed Web of Science ®Google Scholar
• Picard M, Castells MC. Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. Clin Rev Allerg Immunol. April 17, 2014. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol. 1990;8:1263–1268.
   PubMed Web of Science ®Google Scholar
• Cucinotto I, Fiorillo L, Gualtieri S, et al. Nanoparticle albumin bound paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv. 2013;2013:905091.
   Google Scholar
• Sparreboom A, van Zuylen L, Brouwer E, et al. Cremaphor EL mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59:1454–1457.
   PubMed Web of Science ®Google Scholar
• Van Tellingen O, Huizing MT, Panday VR, et al. Cremaphor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer. 1999;81:330–335.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremaphor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–1598.
   PubMed Web of Science ®Google Scholar
• Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol. 1997;15:2414–2419.
   PubMed Web of Science ®Google Scholar
• Lam AP, Sparano JA, Vinciguerra, et al. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol. 2010;33:121–124.
   PubMed Web of Science ®Google Scholar
• Maeda S, Motoi F, Onogawa T, et al. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol. 2011;16:539–545.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Bang S, Park JY, Park SW, Chung JB, Song SY. Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:529–533.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Kulke MH, Fuchs CS, et al. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 2002;94:97–103.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Mavroudis D, Tsavaris N, et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol. 2001;12:101–103.
   PubMed Web of Science ®Google Scholar
• Cascinu S, Gasparini G, Catalano V, et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol. 1999;10:1377–1379.
   PubMed Web of Science ®Google Scholar
• Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14:282–295.
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8:1038–1044.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information: Abraxane (package insert) 2013. Available from: http://www.abraxane.com/downloads/Abraxane_PrescribingInformation.pdf. Accessed October 19, 2014.
   Google Scholar
• Paal K, Muller J, Hegedus L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem. 2001;268:2187–2191.
   PubMedGoogle Scholar
• Gradishar WJ. Albumin-bound paclitaxel: a next generation taxane. Expert Opin Pharmacother. 2006;7:1041–1053.
   PubMed Web of Science ®Google Scholar
• John TA, Vogel SM, Tiruppathi C, Malik AB, Marshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol. 2003;284:L187–L196.
   PubMed Web of Science ®Google Scholar
• Chen T, Liu L, Xu H-X, et al. Significance of caveolin-1 regulators in pancreatic cancer. Asian Pac J Cancer Prev. 2013;14:4501–4507.
   Google Scholar
• Schubert W, Frank PG, Razani B, Park DS, Chow CW, Lisanti MP. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in-vivo. J Biol Chem. 2001;276:8619–8622.
   Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317–1324.
   PubMed Web of Science ®Google Scholar
• Surapaneni MS, Das SK, Das NG. Designing paclitaxel delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol. 2012;2012:623139.
   PubMedGoogle Scholar
• Commisso C, Davidson SM, Soydaner-Azeloglu RG, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497:633–637.
   PubMed Web of Science ®Google Scholar
• Sato N, Fukushima N, Maehara N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003;22:5021–5030.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401.
   PubMed Web of Science ®Google Scholar
• Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25:319–325.
   PubMed Web of Science ®Google Scholar
• Ryu B, Jones J, Hollingsworth MA, et al. Invasion specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res. 2001;61:1833–1838.
   Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548–4554.
   PubMed Web of Science ®Google Scholar
• Neesse A, Frese KK, Chan DS, et al. SPARC independent drug delivery and antitumor effects of nab-paclitaxel in genetically engineered mice. Gut. 2014;63:974–983.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Piaza C, Llei, et al. SPARC analysis in the phase III MPACT trial of nab-paclitaxel plus gemcitabine vs gemcitabine alone for patients with metastatic pancreatic cancer. Ann Oncol. 2014;25 Suppl 2:ii106.
   Google Scholar
• Alvarez R, Musteanu M, Garcia-Garcia E, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109:926–933.
   PubMed Web of Science ®Google Scholar
• Sousa CM, Kimmelman AC. The complex landscape of pancreatic cancer metabolism. Carcinogenesis. 2014;35:1441–1450.
   Web of Science ®Google Scholar
• Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia. 2005;7:17–23.
   PubMed Web of Science ®Google Scholar
• Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39:91–100.
   PubMed Web of Science ®Google Scholar
• Lim JP, Gleeson PA. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol Cell Biol. 2011;89:836–843.
   PubMed Web of Science ®Google Scholar
• Neesse A, Michl P, Tuveson DA, Ellenreider V. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. Z Gastroenterol. 2014;52:360–366.
   Web of Science ®Google Scholar
• Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260–269.
   PubMed Web of Science ®Google Scholar
• Zhang DS, Wang DS, Wang ZQ, et al. Phase I/II study of albumin bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013;71:1065–1072.
   Web of Science ®Google Scholar
• Ko AH, Truong TG, Kantoff E, et al. A phase I trial of nab-paclitaxel, gemcitabine and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012;70:875–881.
   Web of Science ®Google Scholar
• El-Khoueiry AB, Iqbal S, Lenz H, et al. A phase I study of two different schedules of nab-paclitaxel with ascending doses of vandetanib with expansion in patients with pancreatic cancer. J Clin Oncol. 2011;29 Suppl:Abstr 4124.
   Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Fontana E, Sclafani F, Cunningham D. Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel. Gastrointestinal Cancer: Targets and Therapy. 2014;4:89–101.
   Google Scholar